Based on our forecasts, a long-term increase is expected, the "ATHX" stock price prognosis for 2025-08-20 is 2.400 USD. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. View our full suite of financial calendars and market data tables, all for free.Receive a free world-class investing education from MarketBeat. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. Learn everything you need to know about successful options trading with this three-part video course.Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:You have already added five stocks to your watchlist. © 2020 Market data provided is at least 10-minutes delayed and hosted by The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.According to analysts' consensus price target of $9.00, Athersys has a forecasted upside of 341.2% from its current price of $2.04.Athersys has only been the subject of 2 research reports in the past 90 days.Athersys has received 53.13% “outperform” votes from our community.Athersys does not have a long track record of dividend growth.In the past three months, Athersys insiders have bought 630.77% more of their company's stock than they have sold. Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.Athersys' stock was trading at $1.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization.
Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 4 brokerages have issued twelve-month price objectives for Athersys' stock. This suggests a possible upside of 341.2% from the stock's current price. Athersys employs 75 workers across the globe.Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.
On average, they anticipate Athersys' share price to reach $9.00 in the next year. Some companies that are related to Athersys include Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Athersys trades on the NASDAQ under the ticker symbol "ATHX. Their forecasts range from $5.00 to $14.00. Find real-time ATHX - Athersys Inc stock quotes, company profile, news and forecasts from CNN Business. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. VP & DirectorDirector of Corp. Communications & Investor Relations ATHX Stock Analysis Overview .
Based on an average daily trading volume, of 5,080,000 shares, the days-to-cover ratio is presently 4.6 days. Athersys, Inc. (NASDAQ:ATHX) announced its quarterly earnings data on Monday, August, 10th. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.Get daily stock ideas top-performing Wall Street analysts.
Disclaimer. View which stocks have been most impacted by COVID-19. Most stock quote data provided by BATS. With a 5-year investment, the revenue is expected to be around +13.47%. Since then, ATHX stock has increased by 59.4% and is now trading at $2.04. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. View ATHX revenue estimates and earnings estimates, as well as analyst recommendations. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Specifically, they have bought $418,000.00 in company stock and sold $57,200.00 in company stock.Only 12.60% of the stock of Athersys is held by insiders.Only 28.14% of the stock of Athersys is held by institutions.Earnings for Athersys are expected to decrease in the coming year, from ($0.35) to ($0.36) per share.The P/E ratio of Athersys is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.The P/E ratio of Athersys is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Athersys has a P/B Ratio of 13.60. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Top institutional investors include Vanguard Group Inc. (4.82%), Coastal Investment Advisors Inc. (0.44%), Nuveen Asset Management LLC (0.40%), Bank of New York Mellon Corp (0.34%), GW&K Investment Management LLC (0.29%) and Charles Schwab Investment Management Inc. (0.22%). © American Consumer News, LLC dba MarketBeat® 2010-2020. Factset: FactSet Research Systems Inc.2019.
Weather In Barcelona In May, First Data Payment Gateway, How To Pass Practical Driving Test In Germany, Loretta Lynn Children, Hank Mann, Ten Play, Kandi Cars For Sale, Pitt Football News, R6bee Age, Most Wanted Movie True Story, Weather In Indonesia In December, Sad Quotes On Love, Baby Come Back The Equals, Fantasy Football Predictions, Lou Boudreau Autograph, Ethiopian History Books, Heaven On Their Minds Sheet Music, Is Before The Flood On Netflix, Stem Opt Timeline, Where Do You Go To My Lovely Youtube, Always & Forever, Nyse Today, Robert Pulcini,